+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cardiovascular Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5292751
  • Report
  • February 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Merck & Co
  • Novartis AG
  • Pfizer Inc
  • Sanofi S.A
Cardiovascular Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs market as it emerges from the COVID-19 shut down.







Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:

Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cardiovascular Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider cardiovascular drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The cardiovascular drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cardiovascular drugs indicators comparison.

Scope

Markets Covered:
1) By Type: Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs)
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: Merck & Co; Sanofi S.A; Pfizer Inc; Bristol-Myers Squibb Company; Novartis AG

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, cardiovascular drugs indicators comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Cardiovascular Drugs Market

What is the estimated value of the Global Cardiovascular Drugs Market?

The Global Cardiovascular Drugs Market was estimated to be valued at $92.4 billion in 2021.

What is the growth rate of the Global Cardiovascular Drugs Market?

The growth rate of the Global Cardiovascular Drugs Market is 3.9%, with an estimated value of $107.8 billion by 2025.

What is the forecasted size of the Global Cardiovascular Drugs Market?

The Global Cardiovascular Drugs Market is estimated to be worth $107.8 billion by 2025.

Who are the key companies in the Global Cardiovascular Drugs Market?

Key companies in the Global Cardiovascular Drugs Market include Merck & Co, Sanofi S.A, Pfizer Inc, Bristol and Novartis AG.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Merck & Co
  • Novartis AG
  • Pfizer Inc
  • Sanofi S.A

1. Executive Summary2. Report Structure
3. Cardiovascular Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Cardiovascular Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Cardiovascular Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Cardiovascular Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Cardiovascular Drugs Market Trends and Strategies8. Impact of COVID-19 on Cardiovascular Drugs
9. Cardiovascular Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market
10. Cardiovascular Drugs Market Regional Analysis
10.1. Global Cardiovascular Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Cardiovascular Drugs Market, Growth and Market Share Comparison, by Region
11. Cardiovascular Drugs Market Segmentation
11.1. Global Cardiovascular Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Anti-Hypertensive Drugs
  • Hypolipidemics
  • Anti Thrombotics
  • Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs)
11.2. Global Cardiovascular Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
11.3. Global Cardiovascular Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
11.4. Global Cardiovascular Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
11.5. Global Cardiovascular Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs

12. Cardiovascular Drugs Market Metrics
12.1. Cardiovascular Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Cardiovascular Drugs Market Expenditure, 2015-2025, Global
13. Asia-Pacific Cardiovascular Drugs Market
13.1. Asia-Pacific Cardiovascular Drugs Market Overview
  • Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
13.2. Asia-Pacific, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
13.3. Asia-Pacific, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
13.4. Asia-Pacific, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
13.5. Asia-Pacific, Cardiovascular Drugs Market Metrics
13.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, Asia-Pacific Countries
13.6. Asia-Pacific Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7. Asia-Pacific Cardiovascular Drugs Market: Country Analysis
13.7.1. China Cardiovascular Drugs Market
13.7.1.1. China Cardiovascular Drugs Market Overview
13.7.1.2. China Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.1.3. China Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2. Australia Cardiovascular Drugs Market
13.7.2.1. Australia Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2.2. Australia Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.3. Hong Kong Cardiovascular Drugs Market
13.7.3.1. Hong Kong Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4. India Cardiovascular Drugs Market
13.7.4.1. India Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4.2. India Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5. Indonesia Cardiovascular Drugs Market
13.7.5.1. Indonesia Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5.2. Indonesia Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6. Japan Cardiovascular Drugs Market
13.7.6.1. Japan Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6.2. Japan Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.7. Malaysia Cardiovascular Drugs Market
13.7.7.1. Malaysia Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.8. New Zealand Cardiovascular Drugs Market
13.7.8.1. New Zealand Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.9. Philippines Cardiovascular Drugs Market
13.7.9.1. Philippines Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.10. Singapore Cardiovascular Drugs Market
13.7.10.1. Singapore Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11. South Korea Cardiovascular Drugs Market
13.7.11.1. South Korea Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11.2. South Korea Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.12. Thailand Cardiovascular Drugs Market
13.7.12.1. Thailand Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.13. Vietnam Cardiovascular Drugs Market
13.7.13.1. Vietnam Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14. Western Europe Cardiovascular Drugs Market
14.1. Western Europe Cardiovascular Drugs Market Overview
14.2. Western Europe, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
14.3. Western Europe, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Western Europe, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Western Europe, Cardiovascular Drugs Market Metrics
14.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, Western Europe Countries
14.6. Western Europe Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Western Europe Cardiovascular Drugs Market: Country Analysis
14.7.1. Austria Cardiovascular Drugs Market
14.7.1.1. Austria Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Belgium Cardiovascular Drugs Market
14.7.2.1. Belgium Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Denmark Cardiovascular Drugs Market
14.7.3.1. Denmark Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. Finland Cardiovascular Drugs Market
14.7.4.1. Finland Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. France Cardiovascular Drugs Market
14.7.5.1. France Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. France Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Germany Cardiovascular Drugs Market
14.7.6.1. Germany Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Germany Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Ireland Cardiovascular Drugs Market
14.7.7.1. Ireland Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. Italy Cardiovascular Drugs Market
14.7.8.1. Italy Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Netherlands Cardiovascular Drugs Market
14.7.9.1. Netherlands Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Norway Cardiovascular Drugs Market
14.7.10.1. Norway Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. Portugal Cardiovascular Drugs Market
14.7.11.1. Portugal Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Spain Cardiovascular Drugs Market
14.7.12.1. Spain Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Sweden Cardiovascular Drugs Market
14.7.13.1. Sweden Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.14. Switzerland Cardiovascular Drugs Market
14.7.14.1. Switzerland Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15. UK Cardiovascular Drugs Market
14.7.15.1. UK Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15.2. UK Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15. Eastern Europe Cardiovascular Drugs Market
15.1. Eastern Europe Cardiovascular Drugs Market Overview
15.2. Eastern Europe, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
15.3. Eastern Europe, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Eastern Europe, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Eastern Europe, Cardiovascular Drugs Market Metrics
15.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, Eastern Europe Countries
15.6. Eastern Europe Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Eastern Europe Cardiovascular Drugs Market: Country Analysis
15.7.1. Czech Republic Cardiovascular Drugs Market,
15.7.1.1. Czech Republic Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Poland Cardiovascular Drugs Market
15.7.2.1. Poland Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Romania Cardiovascular Drugs Market
15.7.3.1. Romania Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Russia Cardiovascular Drugs Market
15.7.4.1. Russia Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4.2. Russia Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16. North America Cardiovascular Drugs Market
16.1. North America Cardiovascular Drugs Market Overview
16.2. North America, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
16.3. North America, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. North America, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. North America, Cardiovascular Drugs Market Metrics
16.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, North America Countries
16.6. North America Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. North America Cardiovascular Drugs Market: Country Analysis
16.7.1. Canada Cardiovascular Drugs Market
16.7.1.1. Canada Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Mexico Cardiovascular Drugs Market
16.7.2.1. Mexico Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. USA Cardiovascular Drugs Market
16.7.3.1. USA Cardiovascular Drugs Market Overview
16.7.3.2. USA Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3.3. USA Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17. South America Cardiovascular Drugs Market
17.1. South America Cardiovascular Drugs Market Overview
17.2. South America, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
17.3. South America, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. South America, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. South America, Cardiovascular Drugs Market Metrics
17.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, South America Countries
17.6. South America Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. South America Cardiovascular Drugs Market: Country Analysis
17.7.1. Argentina Cardiovascular Drugs Market
17.7.1.1. Argentina Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Brazil Cardiovascular Drugs Market
17.7.1.1. Brazil Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2.2. Brazil Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. Chile Cardiovascular Drugs Market
17.7.3.1. Chile Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.4. Colombia Cardiovascular Drugs Market
17.7.4.1. Colombia Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.5. Peru Cardiovascular Drugs Market
17.7.5.1. Peru Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.6. Venezuela Cardiovascular Drugs Market
17.7.6.1. Venezuela Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18. Middle East Cardiovascular Drugs Market
18.1. Middle East Cardiovascular Drugs Market Overview
18.2. Middle East, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
18.3. Middle East, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. Middle East, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. Middle East, Cardiovascular Drugs Market Metrics
18.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, Middle East Countries
18.6. Middle East Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. Middle East Cardiovascular Drugs Market: Country Analysis
18.7.1. Saudi Arabia Cardiovascular Drugs Market
18.7.1.1. Saudi Arabia Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Israel Cardiovascular Drugs Market
18.7.2.1. Israel Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Turkey Cardiovascular Drugs Market
18.7.3.1. Turkey Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. UAE Cardiovascular Drugs Market
18.7.4.1. UAE Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19. Africa Cardiovascular Drugs Market
19.1. Africa Cardiovascular Drugs Market Overview
19.2. Africa, Cardiovascular Drugs Market, 2020, by Country, Value ($ Billion)
19.3. Africa, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Africa, Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Africa, Cardiovascular Drugs Market Metrics
19.5.1. Per Capita Average Cardiovascular Drugs Expenditure, 2015-2025, Africa Countries
19.6. Africa Cardiovascular Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Africa Cardiovascular Drugs Market: Country Analysis
19.7.1. Egypt Cardiovascular Drugs Market
19.7.1.1. Egypt Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Nigeria Cardiovascular Drugs Market
19.7.2.1. Nigeria Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. South Africa Cardiovascular Drugs Market
19.7.3.1. South Africa Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20. Cardiovascular Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. Merck & Co
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. Sanofi S.A
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Pfizer Inc
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Bristol-Myers Squibb Company
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Novartis AG
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance
21. Key Mergers and Acquisitions in the Cardiovascular Drugs Market
22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)
23. Recommendations
23.1. Global Cardiovascular Drugs Market in 2025 - Growth Countries
23.2. Global Cardiovascular Drugs Market in 2025 - Growth Segments
23.3. Global Cardiovascular Drugs Market in 2025 - Growth Strategies
24. Appendix
24.1. NAICS Definitions of Industry Covered in This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
25. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Merck & Co
  • Novartis AG
  • Pfizer Inc
  • Sanofi S.A
Major companies in the cardiovascular drugs market include Merck & Co; Sanofi S.A; Pfizer Inc; Bristol-Myers Squibb Company and Novartis AG.

The global cardiovascular drugs market is expected to grow from $87.79 billion in 2020 to $92.41 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $107.77 billion in 2025 at a CAGR of 4%.

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The cardiovascular drugs market is segmented into anti-hypertensive drugs; hypolipidemics; anti thrombotics; and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs).

Asia Pacific was the largest region in the global cardiovascular drugs market, accounting for 40% of the market in 2020. North America was the second largest region accounting for 27% of the global cardiovascular drugs market. Africa was the smallest region in the global cardiovascular drugs market.

NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs manufacturers.

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Merck & Co
  • Sanofi S.A
  • Pfizer Inc
  • Bristol-Myers Squibb Company
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...